{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:27:41Z","timestamp":1780104461859,"version":"3.54.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LA\/P\/0058\/2020"],"award-info":[{"award-number":["LA\/P\/0058\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04539\/ 2020"],"award-info":[{"award-number":["UIDP\/04539\/ 2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04539\/2020"],"award-info":[{"award-number":["UIDB\/04539\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["2024\\u20132025"],"award-info":[{"award-number":["2024\\u20132025"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["24397"],"award-info":[{"award-number":["24397"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118817","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T07:46:16Z","timestamp":1763797576000},"page":"118817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Patient-derived neuroblastoma models are sensitive to nucleolin-recognizing liposomal drugs"],"prefix":"10.1016","volume":"193","author":[{"given":"Veronica","family":"Bensa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Lopes-Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Ciampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Voronovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Manuel","family":"Soares-Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Morini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ardito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Gualco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Concetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mazzocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gaggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio Gaetano","family":"Vellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito Alessandro","family":"Lasorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fragola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Brignole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Nuno","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118817_bib1","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118817_bib2","first-page":"515","article-title":"Advancing therapy for neuroblastoma, Nature reviews","volume":"19","author":"Qiu","year":"2022","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118817_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113991","article-title":"Clinical cancer nanomedicines","volume":"385","author":"Pallares","year":"2025","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.biopha.2025.118817_bib4","article-title":"Liposomes for Tumor Targeted Therapy: A Review","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118817_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biochi.2015.03.023","article-title":"The roles of nucleolin subcellular localization in cancer","volume":"113","author":"Berger","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2025.118817_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/1574892808666131119095953","article-title":"Cell surface nucleolin as a target for anti-cancer therapies","volume":"9","author":"Koutsioumpa","year":"2014","journal-title":"Recent Pat. antiCancer Drug Discov."},{"key":"10.1016\/j.biopha.2025.118817_bib7","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/abfb30","article-title":"Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option","volume":"32","author":"Ferrara","year":"2021","journal-title":"Nanotechnology"},{"key":"10.1016\/j.biopha.2025.118817_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104300","article-title":"Nucleolin expression has prognostic value in neuroblastoma patients","volume":"85","author":"Cangelosi","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2025.118817_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13046-021-01993-9","article-title":"Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy","volume":"40","author":"Brignole","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118817_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.200304132","article-title":"Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels","volume":"163","author":"Christian","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118817_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12967-024-04954-w","article-title":"From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models","volume":"22","author":"Capasso","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118817_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.biomaterials.2015.08.007","article-title":"Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination","volume":"69","author":"Fonseca","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2025.118817_bib13","article-title":"Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models","volume":"16","author":"Di Paolo","year":"2020","journal-title":"Small (Weinh. der Bergstr. Ger. )"},{"key":"10.1016\/j.biopha.2025.118817_bib14","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1078-0432.CCR-15-0379","article-title":"Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma","volume":"22","author":"Krytska","year":"2016","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.biopha.2025.118817_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102964","article-title":"Global, regional, and national epidemiology of childhood neuroblastoma (1990-2021): a statistical analysis of incidence, mortality, and DALYs","volume":"79","author":"Nong","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopha.2025.118817_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118817_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27556","article-title":"The challenge of defining \"ultra-high-risk\" neuroblastoma","volume":"66","author":"Morgenstern","year":"2019","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.biopha.2025.118817_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11523-025-01155-3","article-title":"Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed\/Refractory High-Risk Neuroblastoma","volume":"20","author":"Wieczorek","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.biopha.2025.118817_bib19","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118817_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015787","article-title":"Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization","volume":"5","author":"Hovanessian","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2025.118817_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002293","article-title":"Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic\/therapeutic target in GD2neg\/low neuroblastoma variants","volume":"9","author":"Dondero","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118817_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007174","article-title":"Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma","volume":"11","author":"Brignole","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118817_bib23","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118817_bib24","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1158\/0008-5472.CAN-06-2117","article-title":"Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy","volume":"66","author":"Pastorino","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118817_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.biomaterials.2015.07.054","article-title":"Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion","volume":"68","author":"Cossu","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2025.118817_bib26","article-title":"Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers","volume":"15","author":"Pastorino","year":"2019","journal-title":"Small (Weinh. der Bergstr. Ger. )"},{"key":"10.1016\/j.biopha.2025.118817_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2.2.143","article-title":"Caelyx\/Doxil for the treatment of metastatic ovarian and breast cancer","volume":"2","author":"Tejada-Berges","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.biopha.2025.118817_bib28","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2011.142","article-title":"Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma","volume":"19","author":"Di Paolo","year":"2011","journal-title":"Molecular therapy journal American Society Gene Therapy"},{"key":"10.1016\/j.biopha.2025.118817_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113923","article-title":"Clinical trial inclusion in patients with relapsed\/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS","volume":"201","author":"Chaix","year":"2024","journal-title":"European journal cancer (Oxford England 1990)"},{"key":"10.1016\/j.biopha.2025.118817_bib30","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41591-024-03044-0","article-title":"Precision-guided treatment in high-risk pediatric cancers","volume":"30","author":"Lau","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118817_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115423","article-title":"Corrigendum to \"Implementation of paediatric precision oncology into clinical practice: the individualized therapies for children with cancer program 'iTHER'\" [Eur J Cancer 175 (2022) 311-325]","volume":"221","author":"Langenberg","year":"2025","journal-title":"European journal cancer (Oxford England 1990)"},{"key":"10.1016\/j.biopha.2025.118817_bib32","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/s41591-022-01856-6","article-title":"Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer","volume":"28","author":"Church","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118817_bib33","article-title":"Outcome of Children and Adolescents With Relapsed\/Refractory\/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM","volume":"7","author":"Heipertz","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.biopha.2025.118817_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s43018-022-00474-y","article-title":"The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations","volume":"4","author":"Villani","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2025.118817_bib35","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2147\/IJN.S359666","article-title":"Clinical trials of liposomes in children's anticancer therapy: a comprehensive analysis of trials registered on clinicalTrials","volume":"17","author":"Feng","year":"2022","journal-title":"Gov. Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2025.118817_bib36","article-title":"Nanomedicine for pediatric healthcare: a review of the current state and future prospectives","volume":"207","author":"Chen","year":"2025","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arb. fur Pharm. Verfahr. e. V."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222501011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222501011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:58:21Z","timestamp":1777013901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222501011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"alternative-id":["S075333222501011X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118817","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-derived neuroblastoma models are sensitive to nucleolin-recognizing liposomal drugs","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118817"}}